Ligand id: 2770

Name: paclitaxel

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: paclitaxel

Structure and Physico-chemical Properties

2D Structure
Click here for structure editor
Calculated Physico-chemical Properties
Hydrogen bond acceptors 15
Hydrogen bond donors 4
Rotatable bonds 15
Topological polar surface area 221.29
Molecular weight 853.33
XLogP 2.96
No. Lipinski's rules broken 2

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Solvent-based paclitaxel is approved to treat lung, ovarian and breast cancers and Kaposi's sarcoma.
Nab-paclitaxel is designated as an orphan drug by the US FDA, for the treatment of metastatic adenocarcinoma of the pancreas (in combination with gemcitabine). It is fully approved for this indication and for use in certain breast cancer patients (with tumours unresponsive to other chemotherapy, or relapsed disease) and non-small-cell lung cancer (NSCLC).
Mechanism Of Action and Pharmacodynamic Effects
Paclitaxel binds to the β-subunit of tubulin, which prevents the microtubule/paclitaxel complex from disassembling. This prevents normal microtubulin growth and function by stopping the microtubules from shortening and lengthening as they normally would.
External links